ARDT: Post Collapse Recovery detected on 10 Jul 2026

ARDT is forming a post-collapse recovery pattern on the back of an earlier ascending triangle (formed May 26, good strength at 32.0 quality score). Current price at $10.09 sits between key support at $7.95 and resistance at $11.03—a 1.4% gap to test. Structure scores 12.48/15, volume at 12.0/12, and breakout at 10.8/13 indicate solid technical foundation. The overall score of 69.28 and 68% win probability suggest this recovery has institutional conviction behind it. RSI at 55.04 shows neutral momentum—neither overbought nor oversold—providing room for upside move.

ARDT beat Q1 2026 earnings on May 5th, reporting $0.28 per share versus estimates of $0.19, and total revenue grew 7.0% year-over-year to $1,602 million. Adjusted EBITDA increased 26.3% year-over-year to $124 million. However, momentum has stalled: CEO Dave Caspers was elevated in early June on the back of tougher macro backdrop and softer Q2 volumes for hospitals. CFO Alfred Lumsdaine purchased 10,000 shares ($88,100) and Director Robert DeMichiei acquired 11,260 shares ($98,299) on June 8, 2026—strong insider support post-selloff. The company reaffirmed 2026 guidance: revenue $6.4–6.7 billion and adjusted EBITDA $485–535 million. Pattern is forming as leadership stabilizes and insiders buy.

A successful breakout above the $11.03 resistance would target $10.60 conservatively per the measured move. Volume confirmation is critical—current 375k shares traded is below the 20-day average of 586k, suggesting traders are waiting for clarity. The pattern invalidates below the $7.95 support level; any close below that price would signal the recovery has failed. With 68% win probability, historical breakouts from this pattern type suggest breakout attempts face 1–2 weeks of oscillation before establishing trend. ATR at 0.44 (4.36% of price) indicates elevated volatility typical of healthcare sector (beta 1.41), requiring wider stop placement.

Q2 hospital volumes softened, which prompted the CEO transition—a key operational headwind. Payer denials are rising and commercial contracts are only 75% complete for 2026, presenting margin risk. Bank of America lowered its price target from $10 to $9 on June 9, 2026, and Morgan Stanley flagged softer volume commentary. High beta of 1.41 amplifies downside if healthcare sector weakens. Median analyst target is $13.00, but downside dispersion exists. Volume ratio at 0.64 (below average) signals weak follow-through—breakout could fail without conviction buying. No imminent earnings until Q2 results, creating vacuum for negative commentary to pressure stock.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.